RFP for Case Reports/Case Series on Odevixibat

About this program

Ipsen is issuing an RFP for case reports or case series on real-world use of odevixibat for pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) and cholestatic pruritus of Alagille syndrome, with potential support including financial reimbursement and/or study drug supply subject to a written agreement. Eligible applicants include healthcare professionals, scientists, researchers, or institutions; one-page proposals plus a budget must be emailed to InvestigatorSponsoredStudies@ipsen.com by September 30, 2026. Proposals must provide scientific rationale, clinical context, and a description of the odevixibat intervention, include a publication plan, and use de-identified patient data with written patient consent; any adverse events must be reported and applicants must provide a financial disclosure. Accepted proposals will be evaluated for alignment with Ipsen’s interests and, if approved, may receive reimbursement for third‑party medical writing; investigators retain discretion over ISS publication and must comply with applicable laws, ethics, and pharmacovigilance requirements.